- 8.4 percent reduction for patients with any diagnosis
- 10.1 percent reduction for congestive heart failure patients
- 12.0 percent reduction for acute myocardial infarction patients
The FDA today authorized Abbott's (ABT) FreeStyle Libre Pro system, which is used to continually monitor diabetic patients' glucose levels.
The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.
U.S. stocks ended Friday's session lower as a crude oil selloff pressures the energy sector and nerves over next week's Federal Reserve meeting peak.